ArticleJournal of clinical medicine2024
How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review.
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Survival benefit of guideline-directed medical therapy in older patients with heart failure: a systematic review and meta-analysis.Heart (British Cardiac Society) · 2026Pooled it
- Vericiguat in Elderly Patients with Heart Failure and Reduced Ejection Fraction: Clinical Perspectives from Pathophysiology to Implementation.Journal of clinical medicine · 2026Review
- ANMCO position paper E-health integration in cardiology clinical care framework.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Autonomic imbalance in cardiovascular disease: molecular mechanisms and emerging therapeutics.American journal of physiology. Cell physiology · 2025Review
- Impact of Catheter Ablation on Functional Capacity and Cardiac Stress Markers in Patients with Premature Ventricular Contractions.Medical sciences (Basel, Switzerland) · 2025Article
- Management of Atrial Fibrillation in Elderly Patients: A Whole New Ballgame?Journal of clinical medicine · 2025Review
- An Observational Study of Evidence-Based Therapies in Older Patients with Heart Failure with Reduced Ejection Fraction: Insights from a Dedicated Heart Failure Clinic.Journal of clinical medicine · 2024Article
- Acute Coronary Syndrome in Elderly Patients: How to Tackle Them?Journal of clinical medicine · 2024Review
- A Look at Primary and Secondary Prevention in the Elderly: The Two Sides of the Same Coin.Journal of clinical medicine · 2024Review
- A Comprehensive Geriatric Workup and Frailty Assessment in Older Patients with Severe Aortic Stenosis.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta blockers (BBs) play a crucial role in enhancing the quality of life and extending the survival of patients with heart failure and reduced ejection fraction (HFrEF). Initiating the therapy at low doses and gradually titrating the dose upwards is recommended to ensure therapeutic efficacy while mitigating potential adverse effects. Vigilant monitoring for signs of drug intolerance is necessary, with dose adjustments as required. The management of older HF patients requires a case-centered approach, taking into account individual comorbidities, functional status, and frailty. Older adults, however, are often underrepresented in randomized clinical trials, leading to some uncertainty in management strategies as patients with HF in clinical practice are older than those enrolled in trials. The present article performs a scoping review of the past 25 years of published literature on BBs in older HF patients, focusing on age, outcomes, and tolerability. Twelve studies (eight randomized-controlled and four observational) encompassing 26,426 patients were reviewed. The results indicate that BBs represent a viable treatment for older HFrEF patients, offering benefits in symptom management, cardiac function, and overall outcomes. Their role in HF with preserved EF, however, remains uncertain. Further research is warranted to refine treatment strategies and address specific aspects in older adults, including proper dosing, therapeutic adherence, and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.